Jinxin Reproductive 2022 In the first half of the year, 1.138 billion yuan, the revenue of the auxiliary reproductive services was 519 million yuan

On August 31, 2022, Jinxin Reproductive (Code: 01951.HK), a listed company in Hong Kong stocks, released the 2022 fiscal year.

From January 1, 2022 to June 30, 2022, the company's income was 1.138 billion yuan, an increase of 32.46%year-on-year. The company's owner should have a profit of 190 million yuan during the period, an increase of 22.17%year-on-year, and the basic earnings per share were 0.08 yuan.

The company's industry is a health care institution.

其中，辅助生殖服务收入5.19亿元，管理服务收入2.88亿元，流动手术中心设施服务收入3455.50万元，辅助医疗服务收入3846.90万元，妇产儿科医疗服务收入2.02亿元，药品、消耗品及The equipment sales income is 57.17 million yuan.

During the company's reporting period, the total assets at the end of the period were 15.085 billion yuan, and the profit before tax was 234 million yuan.

Jinxin Reproductive Medical Group Co., Ltd. was established on May 3, 2018. The company is the leading supplier of auxiliary reproductive services in China and the United States. According to the Ferrusana report, the auxiliary reproductive medical institutions in the company's China network ranked third in the Chinese auxiliary reproductive service market in 2017 and carried out 18,018 IVF Liaoliao cycles. According to the same indicators, these institutions also ranked first among China's non -state -owned auxiliary reproductive service providers in 2017. According to the Fifrrishalvan report, HRC FERTILITY (including HRC Medical, managed by HRC Management based on the management service agreement) ranked first in the auxiliary reproductive service market in the western United States in 2017, and conducted 4,371 IVF Liaoning cycle in 4,371 IVF Liaoning cycle Essence

- END -